CE VIDEO – Understanding the Role of the Trigeminal Nerve in Ocular Disease
The importance of the trigeminal nerve in ocular function.
This activity is supported by an independent educational grant from Neurolens. The content of this activity was planned and prepared independently by Review Education Group without input from members of Neurolens.
Speaker:
Paul Karpecki, OD, FAAO and Carol Nelson, MD
Release Date:
August 17, 2020
Expiration Date:
July 24, 2023
Estimated time to complete activity:
1 hour
Computer System Requirements:
Access to internet and a web browser is required to complete this activity.
Goal Statement:
The trigeminal nerve plays a major role in ocular function. This course will greatly help you in clinical practice given the impact the trigeminal nerve has on the eye and ocular system.
Educational Objectives:
After completing this activity, the participant should be better able to:
- Describe trigeminal dysphoria.
- Review the neurological mechanism of trigeminal nerve symptomatology.
- Discuss the diagnosis of trigeminal dysphoria.
- Discuss treatment options for trigeminal dysphoria.
Target Audience:
This activity is intended for optometrists who provide primary care optometry services, including but not limited to medical optometric services.
Faculty/Editorial Board:
Paul Karpecki, OD, FAAO
Carol Nelson, MD
Continuing Education Credit:
This activity, COPE Activity Number 119992 is accredited by COPE for continuing education for optometrists. This course is COPE approved for 1 hour of CE credit. Course ID is 68824-NO. Please check your state licensing board to see if this approval counts toward your CE requirement for relicensure.
Reviewed by 
Disclosure of Conflicts of Interest:
Review Education Group (REG) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to REG policy. REG is committed to providing its learners with high quality activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.
Paul Karpecki, OD, FAAO
Consulting fees from Aerie, Alderya, Akorn, Alcon, Allergan, Allysta Pharmaceuticals, Avellino, Azura, Bausch Healthcare, BioTissue, DGH Technology, Dompe, Eyegate, Eyepoint, Eyevance, iCare USA, Imprimis, Ivantis, Jobson/WebMD, Johnson & Johnson, Kala, Keplr Vision, Konan Medical, Maculogix, Mallinckrodt, Novaliq, Novartis, Oasis Medical, Ocular Sciences, Ocular Therapeutix, Oculus, OcuSoft, PECAA, Reichert, Rendia, RxSight, Science Based Health, Sentiss Pharma, Sight Sciences, Sun Pharmaceuticals, Tarsus Medical, TearLab, TLC, Visionix, Vital Tears, Vmax
Contracted research with Sight Sciences, Novartis, Dompe, Bruno Vision
Fees for Non-CME/CE Services from Dompe, Novartis, Sun Pharmaceuticals, Mallinckrodt, Bausch & Lomb, Alcon
Royalties from EyeTherapies
Patent holder with Ophthalmic Resources, Inc.
Ownership interest in Blephex, Oyster Point, Amaros, RxSight, Camium, Cool Doctors, Enchroma, Eyedaptec, Eyedetec, Eyevance, eyeBrain Medical Health, Hui AI, Ivantis, LeGrande, LenTechs, Lubris, Mati Therapeutics, PRN, Ocugen, OcuyMedic, Ocuphire, O Solutions, Omega Ophthalmics, Percept, Regener-Eyes, Silk Technologies, Surface Pharmaceuticals, Tarsus, TearClear, Tearfilm Innovations, TecLens, Visant, KEPLR, Yolia, Bruder Healthcare, Ophthalmic Resources
Carol Nelson, MD
Ownership interest in Neurolens
Planners and Managers
REG planners and managers have nothing to disclose.
Method of Participation Request for Credit:
During the period August 17, 2020 through July 24, 2023 participants must read the learning objectives, faculty disclosures and view the complete educational activity.
If you wish to receive acknowledgment for completing this activity, please complete the post-test and evaluation at the conclusion of this course. Post course tests must receive a score of 70% or better in order for a certificate of completion to be issued.
Media:
Video
Disclosure of Unlabeled Use:
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Disclaimer:
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.
